The drug is among the smaller ones by sales and had 12 month sales of just around $14.0 million in the US.
With this, said Glenmark, its current portfolio consists of 141 products authorized for distribution in the U.S. and 58 generic applications pending before the U.S. FDA.
“In addition to these internal filings, Glenmark continues to identify and explore external development partnerships to supplement and accelerate the growth of its existing pipeline and portfolio,” the company said, without going into details.
Glenmark Pharmaceuticals is a pharmaceutical company headquartered in Mumbai, India that was founded in 1977 by Gracias Saldanha as a generic drug and active pharmaceutical ingredient manufacturer; he named the company after his two sons.
It is ranked among the top 75 Pharma & Biotech companies of the world in terms of revenue. It said it has several molecules in various stages of clinical development and is focused in the areas of oncology, dermatology and respiratory.
The company has significant presence in the branded generics markets across emerging economies including India, and operates 16 manufacturing facilities across five countries, besides six R&D centers.
The Generics business of Glenmark services the requirements of the US and Western European markets. The API or active pharmaceutical ingredients business sells its products in over 80 countries, including the US, various countries in the EU, South America and India.